This is an old revision of this page, as edited by Beetstra (talk | contribs) at 12:22, 31 October 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 12:22, 31 October 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD22 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C2804H4339N783O870S14 |
| Molar mass | 63.5 kDa g·mol |
| (what is this?) (verify) | |
Moxetumomab pasudotox is a mouse monoclonal antibody designed for the treatment of cancer.
Moxetumomab pasudotox was developed by MedImmune, Inc.
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Moxetumomab Pasudotox" (PDF). American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |